Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod.

Journal of cellular and molecular medicine - 1 Oct 2015

Patmanathan Sathya Narayanan, Yap Lee Fah, Murray Paul G, Paterson Ian C

Abstract excerpt

Almost all drugs approved for use in humans possess potentially beneficial 'off-target' effects in addition to their principal activity. In some cases this has allowed for the relatively rapid repurposing of drugs for other indications. In this review we focus on the potential for re-purposing FTY720 (also known as fingolimod, Gilenya(™)), an immunomodulatory drug recently approved for the treatment of multiple...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Delivery Systems

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Repositioning

Share to Phenotype

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 26171944
DOI: 10.1111/jcmm.12635
PMCID: PMC4594675

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod.PMID 26171944Read ↗

FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosisSemantic proximity Read ↗

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.Semantic proximity Read ↗

Sphingosine‐1‐phosphate receptor 1 signalling in T cells: trafficking and beyondSemantic proximity Read ↗

Demethylzeylasteral inhibits glioma growth by regulating the miR-30e-5p/MYBL2 axisSemantic proximity Read ↗

Disease-modifying strategies: Targeting protein kinases in multiple sclerosis and other autoimmune disordersSemantic proximity Read ↗

Small-Molecule Protein Kinase Inhibitors and Their Effects on the Immune System: Implications for Cancer TreatmentSemantic proximity Read ↗

Masitinib is an oral, brain penetrant inhibitor of microglial and mast cell activity with neuroprotective potential in progressive forms of multiple sclerosisSemantic proximity Read ↗

The Impact of Sphinogosine-1-Phosphate Receptor Modulators on COVID-19 and SARS-CoV-2 VaccinationSemantic proximity Read ↗

Proteomics and phosphoproteomics profiling of the co-formulation of type I and II interferons, HeberFERON, in the glioblastoma-derived cell line U-87 MGSemantic proximity Read ↗

Mechanistic insights into the therapeutic potential of β-elemene on glioma and other central nervous system diseasesSemantic proximity Read ↗

A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferationSemantic proximity Read ↗

Fyn Kinase in Brain Diseases and Cancer: The Search for InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.